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ABSTRACT
Introduction: As the therapeutic landscape for
rheumatoid arthritis (RA) continues to change,
it is relevant to examine current treatment
patterns among rheumatologists. The purpose
of this study was to identify attitudes and
practices of US rheumatologists with respect to
RA.
Methods: Nine-hundred and one US-practicing
rheumatologists were sent electronic invites (via
email or fax) to participate in a case-vignette
survey in April 2013. All respondents were
currently practicing rheumatology and seeing
at least one RA patient per week. The survey
examined current attitudes, existing
knowledge, management choices and
perceived barriers in the management of RA.
Data collection stopped once 125 responses
were received.
Results: Approximately half of the 125
respondents were very familiar with current
clinical practice guidelines for RA diagnosis and
management. There was no consensus on
which validated tools to use when assessing
RA severity, with 54% using Physician Global
Assessment and 34% using Disease Activity
Score 28 at initial assessment. Most
respondents (74%) used methotrexate (MTX)
as initial therapy for a newly diagnosed RA
patient. Eighty-six percent of respondents
would add a tumor necrosis factor inhibitor
(TNFi) when MTX alone could not control RA.
There was no consensus on which treatment
should be used when a TNFi is ineffective. The
majority of respondents (66% of respondents)
would prescribe TNFis indefinitely in patients
with continued response. If a patient was in
stable remission on MTX and a TNFi,
respondents were most likely to maintain this
regimen (53% of respondents); a notable
minority (43%) would lower the MTX dose.
When prescribing biologics, respondents were
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most concerned with infection; infection was
considered a very significant barrier to biologic
use. Although 98% of respondents indicated
that they personally educate patients about RA,
only 42% provide written material.
Conclusions: The lack of consistency in
responses suggests that rheumatologists may
benefit from continuing medical education on;
clinical practice guidelines; the most recent
evidence for management of patients in
remission; the use of biologic agents after
infection; and management of patients with
RA and comorbidities.
Keywords: Biologic agent; Guidelines; Practice
pattern; Prescribing behavior; Rheumatoid
arthritis; Rheumatology
INTRODUCTION
More than 1 million individuals in the United
States are living with rheumatoid arthritis (RA)
[1]. Strong evidence now suggests that early
diagnosis and aggressive treatment alter the
natural history of RA [2]. Treatment is usually
initiated with a synthetic, non-biologic, disease-
modifying antirheumatic drug (DMARD) to
decrease symptoms, limit joint damage, and
improve long-term outcomes [3, 4]. As a well-
tolerated, once-weekly oral agent, methotrexate
(MTX) is the cornerstone of many treatment
regimens and usually the initial DMARD
selected for mild, moderate, or severe disease
[3, 5]. Over the last decade, several new and
potent DMARDs have been approved by the US
Food and Drug Administration for the
management of RA [6]. These agents, biologic
DMARDs, block the effects of cytokines or of
immune effector cells or their cell-to-cell
interactions [7]. Use of these agents is
generally reserved for patients who have failed
or are resistant to non-biologic DMARDs, or
who have a high level of disease activity at the
time of diagnosis and features of poor prognosis
[8].
As the therapeutic landscape for RA
continues to change, it seems especially
relevant to examine treatment patterns for RA
to understand how US rheumatologists
approach the management of the disease.
Several investigators have recently used
database information to retroactively elucidate
rheumatologists’ practice patterns. Based on an
electronic health record review, Adhikesavan
et al. [9] evaluated the performance of 15
rheumatologists who practice in an integrated
health care delivery system. The
rheumatologists’ practices were compared with
six quality indicators established by the
American College of Rheumatology (ACR).
These investigators found that three of the
indicators, RA DMARD use, intervention if RA
became worse, and MTX risk discussion, were
met for high percentages of patients (94, 85,
and 87% respectively of the 1,062 patient
records reviewed). Percentages of patient
records meeting the indicators were lower for
RA core data set (69%), MTX baseline studies
(41%), and MTX follow-up studies (46%).
Because this study focused on a single health
care system, the authors proposed to address
quality gaps by redesigning the process used to
manage patients with RA. Curtis et al. [10]
analyzed data from the Consortium of
Rheumatology Researchers of North America
(CORRONA) to try to determine the impact of
rheumatologists’ RA treatment preference on
the selection of treatment regimen,
independent of patient characteristics. The
investigators identified biologic naı¨ve RA
patients enrolled in CORRONA who were
newly starting therapy with either an anti-
tumor necrosis factor (TNF) agent or with a
DMARD from 2001 to 2008. In addition, based
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on the data for the patients’ rheumatologists
from the previous calendar year, the authors
determined the prescribing patterns of each
rheumatologist with respect to anti-TNF agents.
The investigators concluded that physician
preference is an important factor in whether
patients are prescribed anti-TNF agents [10].
Bagheri and Wallace analyzed data from a
Southern California pharmacy database, Rx
Biotech, to describe prescribing trends for RA
biologic therapies by 231 rheumatologists in
that region from 2008 to 2010 [11]. They found
that anti-TNF agents as a class were the
predominant choice of therapy (92.6%) for RA
patients seen by private practitioners. Further,
the use of etanercept, adalimumab, or
infliximab as a proportion of all biologic
agents prescribed to RA patients decreased
from 93.6 to 75.7%, while two newer agents,
golimumab and certolizumab, accounted for
17% of new RA treatments [11]. Harrold et al.
[12] used data from the CORRONA registry to
evaluate rheumatologists’ prescribing patterns
before and after the 2008 publication of the
ACR RA treatment recommendations. These
investigators found that publication of the
guidelines did not significantly change
management of patients with active RA [12].
To support the most relevant and effective
educational activities for rheumatologists
throughout the US, there must be an
understanding not only of the practice gaps
related to standards of care, but also the
readiness of US rheumatologists to change
their practice decisions, and the barriers and
challenges they face in managing their patients.
The information gathered through prospective
assessment allows for the delivery of more
effective and tailored educational activities
based on specific audience needs in order to
reduce barriers to care. Furthermore, the
information gathered in this type of
assessment can be used as a baseline to
accurately and objectively measure the
outcomes and effectiveness of future
educational initiatives. This national study was
conducted to prospectively evaluate current US
rheumatologists’ practice patterns with regard
to the diagnosis and management of RA,
familiarity and agreement with guidelines for
classification and treatment of RA, and methods
of patient communication.
METHODS
A case-vignette survey was developed to
examine rheumatologists’ attitudes toward,
knowledge and decisions about, and barriers
to, the management of RA. The survey
consisted of three patient case vignettes—a
newly diagnosed patient, a patient with
progressive disease and a patient in remission.
There were 15 multiple choice questions and 4
Likert scale questions. Invitations for the
online survey were distributed to a random
sample of US-based practicing rheumatologists
by email and fax in April 2013. Criteria for
inclusion in the sample were that the
respondent must be currently practicing
rheumatology and see at least one patient
with RA per week. Invitations to participate
were sent to 901 US rheumatologists based on
information available in the Annual American
Medical Association (AMA) Physician
Characteristics and Distribution US report,
2011 version; data collection was stopped
when 125 surveys were completed. To
adequately power the survey, 125 responses
were collected, providing a margin of error of
±8% at a confidence interval of 95%. When
adequate numbers of surveys were taken, data
collection was stopped.
All statistical analyses for the survey data
were completed with PASW Statistics 18 (SPSS,
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Chicago, IL). Descriptive statistics were used to
summarize survey responses.
Compliance with Ethics Guidelines
This study does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Respondent Demographics
Respondent demographics are shown in
Table 1. The respondent population varied
from the national population of
rheumatologists as represented in the AMA
report in that the study population contained
significantly more males and more solo
practitioners; all other demographics were
nationally representative. Respondents were
experienced rheumatologists, with a mean of
28 years since medical school graduation, and
seeing, on average, 33 patients per week with RA
(range 5–80 RA patients per week).
Survey Responses
RA Management and Treatment Guidelines
When asked about their familiarity with
different RA management guidelines, 58% of
respondents said they were very familiar with
the 2012 update of the 2008 American College
of Rheumatology (ACR) recommendations
regarding the use of DMARDS and biologic
agents [8], while 54% reported that they were
very familiar with the 2010 RA European League
Against Rheumatism (EULAR) or ACR
classification criteria, and 39% said they were
very familiar with the EULAR recommendations
[13] for managing RA with synthetic and
biological disease-modifying antirheumatic
drugs (Table 2). Despite this, almost all
respondents agreed with the guideline-
recommended classification criteria for RA
(Table 2). However, 23% disagreed with the
guideline recommendations for DMARD
therapy in patients with early RA, and 31%
disagreed with the guideline recommendation
regarding tapering biologic DMARDS for
patients in persistent remission.
Diagnosis and Ongoing Evaluation
A total of 18 different indices were used to assess
RA disease severity at diagnosis, during
treatment, or both (Table 3). Physician global
assessment (PGA) was most commonly used by
respondents, followed by the Disease Activity
Score 28 (DAS 28), Routine Assessment of
Patient Index Data 3 (RAPID3), Clinical
Disease Activity Index (CDAI), and multi-
biomarker disease activity test (VectraDA);
approximately one-quarter (26%) used less
common methods. Notably, the five most
common measures were almost always used
both at diagnosis and during treatment, and
there was a high correlation for use of PGA,
DAS28, and RAPID3 for both phases of
management.
Disease Management Three patient scenarios
were presented to the survey respondents to
assess their knowledge and practice patterns.
Managing a Newly Diagnosed Patient with RA
Respondents were presented with a patient
scenario of a 34-year-old woman with 8 weeks
of pain in her hands and wrists and an hour of
morning stiffness, but no rash, diarrhea, or low
back pain. Over-the-counter (OTC) naproxen
provided some pain relief. She had tenderness
and swelling of the left wrist, 2
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metacarpophalangeal (MCP) joints on each
hand, 2 proximal interphalangeal (PIP) joints
on each hand, a strongly positive rheumatoid
factor (RF), and an erythrocyte sedimentation
rate (ESR) of 46. Methotrexate was selected by
74% of respondents as first-line long-term
therapy. A minority of respondents would
initiate treatment aggressively using triple
DMARD therapy (MTX, hydroxychloroquine
and sulfasalazine) or a TNF inhibitor (TNFi); 9
and 6%, respectively. Another small group of
respondents elected to treat with either
hydroxychloroquine alone (10%) or
prescription-strength non-steroidal anti-
inflammatories (NSAIDs) (2%), regimens that
have little or no effect on the underlying disease
process.
Patient with RA No Longer Controlled by
MTX A case was presented of a 42-year-old
man, diagnosed with RA at age 38 years, who
had been well controlled with weekly oral MTX
20 mg and folic acid and who had increased
pain/swelling in both hands and feet; 2 h of
morning stiffness; bilateral wrist synovitis;
synovitis of multiple MCP, PIP, and MTP
joints; RAPID3 score of 16.3; and a DAS28
score of 5.2. Most respondents (86%) would
add a biologic agent to the MTX regimen, 7%
would switch to subcutaneous MTX, 2% would
add hydroxychloroquine and sulfasalazine, and
6% would choose another strategy.
Respondents were informed that this patient
had developed an infection (prostatitis). When
asked about the proper time to restart a TNFi for
Table 1 Demographic characteristics of survey respondents
Rheumatologists (n 5 125)
N Sample (%) US average (%)
Patients seen per week with RA, mean (SD) 33 (25) – N/A
Years since medical school graduation, mean (SD) 28 (9) – N/A
Gender (% male) 98 78 61
Trained in US 89 71 72
Practice location
Urban 47 38 N/A
Suburban 71 57 N/A
Rural 7 5 N/A
Present employment
Solo private 41 33 16
Group private 68 54 44
Non-private (government, academic, or other) 16 13 40
Major professional activity
Direct patient care 123 98 82
Other 2 2 18
Based on the Annual American Medical Association Physician Characteristics and Distribution US report, 2011
SD standard deviation
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this patient after a single infection, 86%
rheumatologists reported that they would do
so immediately, while 8% would wait until the
patient has a flare of RA, 3% would never restart
the TNFi, and 3% selected other.
Patient with RA in Remission on a MTX and
TNFi Regimen Another patient scenario,
45-year-old woman with RA in remission on
MTX and TNFi, was presented to respondents;
two-thirds (66%) would continue a TNFi
Table 2 Respondent familiarity with RA guidelines
(n 5 125)
N %
(A) How familiar are you with the following guidelines for the management of RA?
2012 update of the 2008 ACR recommendations for the use of DMARDs and biologic agents in the treatment of RA
Very familiar 73 58
Somewhat familiar 47 38
Not familiar 5 4
2010 RA classiﬁcation criteria: an ACR/EULAR collaborative initiative
Very familiar 68 54
Somewhat familiar 53 42
Not familiar 4 3
EULAR recommendations for the management of RA with synthetic and biological DMARDs (2010)
Very familiar 49 39
Somewhat familiar 60 48
Not familiar 16 13
(B) Please specify your agreement with the following statements
The classiﬁcation criteria for RA include joint involvement, serology (rheumatoid factor and anti-citrullinated protein
antibody), acute phase reactants (CRP and ESR), and duration of symptoms
Agree 118 94
Disagree 7 6
Patients with early RA who have moderate or high disease activity and poor prognostic features should be started on
DMARD combination therapy (including double and triple therapy)
Agree 96 77
Disagree 29 23
If a patient is in persistent remission after having tapered glucocorticoids, one can consider tapering biological DMARDs,
especially if this treatment is combined with a synthetic DMARD
Agree 86 69
Disagree 39 31
ACR American College of Rheumatology, CRP C-reactive protein, DMARD disease-modifying antirheumatic drug, ESR
erythrocyte sedimentation rate, EULAR European League Against Rheumatism, RA rheumatoid arthritis
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indefinitely for a patient who is in remission
(DAS 28 score of 2.3) while taking MTX and a
TNFi; however, 12% said that they would stop
the TNFi B1 year after the patient achieved
remission, and 13% would stop 1–2 years after
achieving remission. Nine percent of
respondents were unsure as to how long this
patient should remain on the TNFi.
When respondents were given a selection of
five possible therapeutic changes that they
could make in the regimen for a patient whose
RA has been well controlled by MTX and a TNFi
for 2 years, 53% would not change the regimen,
43% would reduce the dose of MTX, 2% would
reduce the dose of TNFi, 1% would discontinue
the TNFi, and 1% would discontinue the MTX.
Rheumatologists were evenly split over what
to do when a TNFi was ineffective. Forty-eight
percent of respondents would try a different
TNFi, while 49% would opt for a biologic agent
from a different class, 1% would not start
another agent, 1% would start a non-biologic
DMARD, and 2% selected other. A difference
was found between rheumatologists in solo
practice versus those in group practice, with
63% of those in solo practice opting for a
biologic agent from another class while 41% of
those in group practice reported that they
would do so.
Biologic Therapy: Knowledge and Attitudes
Prior to starting a biologic therapy, most
respondents (87%) would order hepatitis B
serologies, and nearly all would order a test for
tuberculosis (TB) with either a tuberculin skin
test or QuantiFERON (66 and 46%, respectively;
Fig. 1). Hepatitis C serologies would be obtained
by a large majority (79%) of respondents, and a
small percentage (14%) would test for HIV.
Most respondents would be very likely to
stop biologic therapy for a patient with RA
because of serious side effects, lack of efficacy, or
infection. In addition, approximately two-
thirds (62%) said they would be very likely to
stop biologic therapy for an infusion reaction
and 21% would be ‘very likely’ to stop for an
injection site reaction. Only 9% said they would
be very likely to stop a biologic therapy because
the patient was in remission; however, 42% said
they would be ‘somewhat likely’ to do so
(Fig. 2a).
When asked about their level of concern
regarding potential toxicities of biologic agents,
half of respondents were very concerned about
bacterial infections, and 43% were very
concerned about opportunistic infections,
including TB. A quarter or fewer of
respondents were very concerned about
infusion reactions, lymphoma and other
Fig. 1 Tests routinely ordered prior to starting a patient with rheumatoid arthritis (RA) on biologic therapy for the ﬁrst
time. Respondents were able to ‘‘select all that apply’’
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malignancies (27, 22 and 18%, respectively;
Fig. 2b).
Recurrent infections were considered a very
significant barrier to prescribing biologic agents
to the large majority (80%) of respondents.
Patient comorbidities and insurance restrictions
that limit physicians to prescribing a specific
agent or agents in the class were also regarded as
very significant barriers (Fig. 2c).
Patient Communication
Almost all (98%) respondents indicated that
they provide the initial education to their
patients about RA and RA medications
Fig. 2 Attitudes toward biologic therapy for patients with
rheumatoid arthritis (RA), including: a likelihood of
stopping a biologic therapy in certain situations;
b concerns about toxicity of biologic agents; and
c barriers to prescribing biologic agents in patients with
RA. Respondents were asked to rate each question on a
10-point Likert scale
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through personal discussions. Less than half
(42%) of respondents said they would provide
written materials about RA to newly diagnosed
patients, and 50% would provide written
materials about RA medicines. Only 15% of
respondents would refer patients to websites
to learn about RA, and even fewer (6%) would
do so to help educate patients on RA
medicines. A nurse or physician assistant
would provide a patient with initial
education about the disease of RA for 10% of
respondents and 6% of respondents have a
nurse or other individual discuss the
management of RA with patients.
The majority of respondents spend less than
20 min engaged in educational conversations
with their patients, regardless of the subject
matter (Fig. 3).
DISCUSSION
Approaches to the management of RA continue
to evolve based on an increased understanding
of its pathogenesis and comorbidities and with
the development of new agents to address these
issues. In the past decade, many highly effective
DMARDs with a variety of mechanisms of
action have been developed. To address the
availability of these new agents, both the ACR
and EULAR have recently updated their RA
management guideline documents. As
knowledge about RA increases, and as novel
agents to treat it become available, it is
important to assess rheumatologists’ practice
patterns with respect to managing the disease.
This includes elucidating rheumatologists’
knowledge of and attitudes about new
Fig. 3 Amount of time spent by respondents and/or their ofﬁce staff educating patients about rheumatoid arthritis (RA)
during ﬁrst and subsequent visits, and about any new medication prescribed
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DMARDs and about society guidelines for using
them. Gathering information on barriers that
may prevent the use of these agents can help
focus educational strategies for overcoming
them. However, few recent studies have been
published on this topic. This study adds to the
available information and helps to inform
future education for rheumatologists.
Less than two-thirds of survey respondents
said they were very familiar with the 2012 ACR
RA guideline update and less than half were
very familiar with the EULAR RA guidelines.
Despite this, most respondents in the current
study elected to treat a newly diagnosed RA
patient using MTX monotherapy. This is
consistent with the older 2008 ACR guidelines,
which state that MTX or leflunomide
monotherapy can be used for patients with all
disease durations and for all degrees of disease
activity [14]; the 2012 ACR guideline update
does not distinguish between DMARDs for use
as monotherapy in newly diagnosed patients
with low disease activity and for moderate or
high disease activity with the absence of poor
prognostic features. The 2010 EULAR guidelines
(which were in place when the survey was
conducted) and the 2013 update to the EULAR
guidelines [15] (subsequently published in
October 2013) suggest MTX as initial therapy;
indeed, the recommendations note ‘‘MTX is
considered the anchor drug in RA.’’
For a patient with RA for whom MTX
monotherapy was no longer sufficient, most
respondents would start the patient on a TNFi,
consistent with both the 2012 ACR RA
guidelines and the 2010 EULAR guidelines; of
note, the 2013 EULAR guidelines have
broadened to include other biologic DMARDs
(abatacept, tocilizumab, and under certain
circumstances rituximab) in addition to TNFis.
The lack of knowledge of recent guideline
revisions demonstrated by respondents
suggests recent guideline updates may be an
important area for additional medical education
of rheumatologists. In addition, subsequent to
this survey, the results of two research studies
demonstrated that use of triple therapy (MTX,
sulfasalazine, hydroxychloroquine) is not
inferior to the use of MTX and etanercept,
either as first-line therapy or as step-up after
failure of MTX monotherapy [16, 17]. Future
education may include information about this
alternative management strategy.
This study uncovered a lack of consensus
among respondents about the management of
patients who have stable disease while on MTX
and TNFis. When asked about how long
patients should remain on TNFis, two-thirds of
respondents would continue the TNFi
indefinitely but one-quarter would stop the
TNFi within two years. However, when asked a
more general question, how (if at all) they
would change therapy for a patient in remission
on MTX and a TNFi, just over half would make
no changes while 43% would reduce the MTX
and not the TNFi. There is currently a lack of
data to inform rheumatologists’ practices in this
regard, and it remains an area of ongoing
research. The recently published PRESERVE
trial (NCT00565409) found that, for patients
with RA who had been on MTX and etanercept
therapy, those randomized to either
conventional or half doses of etanercept in
combination with MTX were significantly more
likely to maintain low RA disease activity
compared with those randomized to MTX
alone (etanercept therapy stopped) [18].
Conversely, another recently published trial
involving an early RA population, OPTIMA
(NCT00420927) found that a higher
proportion of trial patients initially treated
with a TNFi and MTX achieved stable low
disease activity compared with those treated
with MTX monotherapy; however, once stable,
Rheumatol Ther (2014) 1:31–44 41
outcomes were the same whether the TNFi was
continued or withdrawn [19]. Many
rheumatologists may elect to reduce the dose
of MTX because patients don’t feel well when
taking it; however, biologic DMARDs are more
effective when given in combination with MTX,
although the minimal dose of MTX necessary to
achieve this effect is not known. In addition,
there is ongoing research into the
cardiovascular benefits of MTX monotherapy;
whether this information can be extrapolated to
the use of MTX in combination with biologic
DMARDs and whether cardiovascular benefit is
related to disease control rather than a specific
agent are areas for future research. This is an
area where rheumatologists will likely need
ongoing education as the results of
investigations continue to be published.
Respondents’ attitudes about biologic
therapy also reveal areas where there is a need
for further education. The majority of
rheumatologists would perform hepatitis B
and C serology testing, which may influence
agent selection [8]. Most would appropriately
stop biologic therapy because of serious side
effects, lack of efficacy, or infection. However,
two-thirds of respondents would stop an RA
patient’s biologic therapy because of an
infusion reaction and one-fifth would stop
biologic therapy if the patient had an
injection site reaction. In addition, a majority
of respondents thought that recurrent
infections and patient comorbidities were very
significant barriers to prescribing biologic
agents. These are areas where further
education may mitigate the barriers to using
biologic agents.
Patient education about RA is crucial to
promoting adherence to treatment regimens.
Although 98% of respondents say they
personally educate patients about RA, most
respondents spend less than 20 min engaged
in educating patients about RA at any visit. In
addition, less than half of respondents provide
patient materials about RA, refer patients to
specific websites about RA, or have their nurse
or physician assistant discuss RA with patients.
Although physician education cannot address
the lack of time available to spend educating
patients, providing rheumatologists with
resources for patient education (e.g. printed
handouts and links to patient-appropriate
websites) would form a useful part of an
educational program.
Limitations
This study used a case-vignette survey as a
surrogate measure of rheumatologists’ skills and
knowledge and did not attempt to verify any
information with chart audits or direct
observation of practice. However, the use of
case vignettes (as compared with chart review
and standardized patients) has been shown to
provide valid and reliable data on clinicians’
actual practice patterns [20]. The three clinical
scenarios that were used in this study do not
cover the full spectrum of RA patient scenarios.
Future studies should investigate other
situations, patient types, and comorbidities in
order to be more inclusive of the practice
patterns used in the US. The study population
contained significantly more male respondents
and solo practitioners than the population of
rheumatologists listed in the AMA 2011 report,
which could have affected responses. There may
have been a responder bias based on
rheumatologists’ willingness to respond to
online surveys, time availability, or other
responder or non-responder characteristics.
Finally, the small honorarium offered to
complete the study and limiting the survey to
the first 125 responses could have established a
selection bias in rheumatologist responses.
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CONCLUSION
Although the results of this study indicate that
the respondents were not very familiar with
current RA guidelines, it did highlight they are
providing guideline-congruent care. We found
disagreement on how to manage a patient in
remission amongst respondents; however,
evidence for any particular strategy is lacking.
Ongoing clinical trials may provide direction in
the future. In addition, these rheumatologists
are concerned about infection in patients taking
biologic agents, management of infusion
reactions and injection site reactions, and
managing patients with comorbidities. Some
of these challenges can be addressed through
continuing medical education. Knowledge gaps
highlighted by this study, and therefore,
potential areas for improved education in
rheumatology, include: (1) EULAR and ACR
recommendations for classification and
treatment of RA; (2) most recent evidence for
management of patients in remission; (3) use of
biologic agents after infection; and (4)
management of patients with RA and
comorbidities.
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